Cited by 430Neuropeptides and Animal PhysiologyHeart Rate Variability and Autonomic ControlRegulation of Appetite and Obesity

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons

Open access

Yamamoto, Hiroshi, Lee, Charlotte E., Marcus, Jacob N., Williams, Todd D., Overton, J. Michael, Lopez, Marisol E., Hollenberg, Anthony N., Baggio, Laurie, Saper, Clifford B., Drucker, Daniel J., Elmquist, Joel K.·2002·Journal of Clinical Investigation

DOI 10.1172/jci0215595

Open this paper in CoChat — free account Open PDF

Abstract

Glucagon-like peptide-1 (GLP-1) released from the gut functions as an incretin that stimulates insulin secretion.GLP-1 is also a brain neuropeptide that controls feeding and drinking behavior and gastric emptying and elicits neuroendocrine responses including development of conditioned taste aversion.Although GLP-1 receptor (GLP-1R) agonists are under development for the treatment of diabetes, GLP-1 administration may increase blood pressure and heart rate in vivo.We report here that centrally and peripherally administered GLP-1R agonists dose-dependently increased blood pressure and heart rate.GLP-1R activation induced c-fos expression in the adrenal medulla and neurons in autonomic control sites in the rat brain, including medullary catecholamine neurons providing input to sympathetic preganglionic neurons.Furthermore, GLP-1R agonists rapidly activated tyrosine hydroxylase transcription in brainstem catecholamine neurons.These findings suggest that the central GLP-1 system represents a regulator of sympathetic outflow leading to downstream activation of cardiovascular responses in vivo.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1172/jci0215595

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Differential expression of orexin receptors 1 and 2 in the rat brain
Marcus, J. N., Aschkenasi, C. J., Lee, C. E., Chemelli, R. M., Saper, C. B., Yanagisawa, M., & Elmquist, J. K. (2001) · Journal of Comparative Neurology · doi:10.1002/cne.1190 · Cited by 1,659
Self-citation
Direct hypothalamo-autonomic connections
Saper, C. B., Loewy, A. D., Swanson, L. W., & Cowan, W. M. (1976) · Brain Research · doi:10.1016/0006-8993(76)90738-1 · Cited by 1,199
Self-citation
Immunohistochemical identification of neurons in the paraventricular nucleus of the hypothalamus that project to the medulla or to the spinal cord in the rat
Sawchenko, P. E., & Swanson, L. W. (1982) · Journal of Comparative Neurology · doi:10.1002/cne.902050306 · Cited by 1,150
Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.
Göke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837
Leptin Activates Hypothalamic CART Neurons Projecting to the Spinal Cord
Elias, C. F., Lee, C., Kelly, J., Aschkenasi, C. J., Ahima, R. S., Couceyro, P. R., Kuhar, M. J., Saper, C. B., & Elmquist, J. K. (1998) · Neuron · doi:10.1016/s0896-6273(00)80656-x · Cited by 809
Self-citation
A functional anatomical analysis of central pathways subserving the effects of interleukin-1 on stress-related neuroendocrine neurons
Ericsson, A. B., Kovacs, K., & Sawchenko, P. E. (1994) · Journal of Neuroscience · doi:10.1523/jneurosci.14-02-00897.1994 · Cited by 679
Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem
Larsen, P. J., Tang-Christensen, M., Holst, J. J., & Ørskov, C. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00434-4 · Cited by 663
Glucagon-Like Peptides
Drucker, D. J. (1998) · Diabetes · doi:10.2337/diab.47.2.159 · Cited by 598
Self-citation
A general pattern of CNS innervation of the sympathetic outflow demonstrated by transneuronal pseudorabies viral infections
Strack, A. M., Sawyer, W. B., Hughes, J., Platt, K. B., & Loewy, A. D. (1989) · Brain Research · doi:10.1016/0006-8993(89)90098-x · Cited by 591

Flagged first, then by citations

Show all 44 references

Research works printed but not linked: 6

Van Dijk, 1996, Am J Physiol, 271, R1096
Thiele, 1997, Am J Physiol, 272, R726
Rinaman, 1999, Am J Physiol, 277, R582
Rinaman, 1999, Am J Physiol, 277, R1537
Barragan, 1994, Am J Physiol, 266, E459
Barragan, 1999, Am J Physiol, 277, E784

Sorted by citations

Items 101–200 of 430

A VGF-Derived Peptide Attenuates Development of Type 2 Diabetes via Enhancement of Islet β-Cell Survival and Function
Stephens, S. B., Schisler, J. C., Hohmeier, H. E., An, J., Sun, A. Y., Pitt, G. S., & Newgard, C. B. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.05.011 · Cited by 102
PPG neurons of the lower brain stem and their role in brain GLP-1 receptor activation
Trapp, S., & Cork, S. C. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00333.2015 · Cited by 103
Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans
Bharucha, A. E., Charkoudian, N., Andrews, C. N., Camilleri, M., Sletten, D., Zinsmeister, A. R., & Low, P. A. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00153.2008 · Cited by 98
The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy
Hansen, H. H., Barkholt, P., Fabricius, K., Jelsing, J., Terwel, D., Pyke, C., Knudsen, L. B., & Vrang, N. (2015) · Brain Research · doi:10.1016/j.brainres.2015.12.052 · Cited by 99
Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety
Nathanson, D., Ullman, B., Löfström, U., HEDMAN, A. G., Frick, M., Sjöholm, Å., & Nyström, T. (2012) · Diabetologia · doi:10.1007/s00125-011-2440-x · Cited by 96
Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study
Jaiswal, M., Martin, C. L., Brown, M. B., Callaghan, B. C., Albers, J. W., Feldman, E. L., & Pop‐Busui, R. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.07.013 · Cited by 95
Exendin-4 decreases amphetamine-induced locomotor activity
Erreger, K., Davis, A. R., Poe, A. M., Greig, N. H., Stanwood, G. D., & Galli, A. (2012) · Physiology & Behavior · doi:10.1016/j.physbeh.2012.03.014 · Cited by 96
GLP-1 Agonists and Blood Pressure: A Review of the Evidence
Goud, A., Zhong, J., Peters, M. C., Brook, R. D., & Rajagopalan, S. (2016) · Current Hypertension Reports · doi:10.1007/s11906-015-0621-6 · Cited by 96
The gut hormone glucagon-like peptide-1 produced in brain: is this physiologically relevant?
Trapp, S., & Richards, J. E. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.09.006 · Cited by 93
Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects
Steinert, R. E., Poller, B., Castelli, M., Drewe, J., & Beglinger, C. (2010) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2010.29663 · Cited by 94
Liraglutide treatment reduced interleukin‐6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy
Brock, C., Hansen, C. S., Karmisholt, J., Møller, H. J., Juhl, A. H., Farmer, A. D., Drewes, A. M., Riahi, S., Lervang, H. H., Jakobsen, P. E., et al. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14063 · Cited by 95
Glucagon-like peptide-1 (7–36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium
Kavianipour, M., Ehlers, M. R., Malmberg, K., Ronquist, G., Rydén, L., Wikström, G., & Gutniak, M. (2003) · Peptides · doi:10.1016/s0196-9781(03)00108-6 · Cited by 90
Peripheral tissue–brain interactions in the regulation of food intake
López, M., Tovar, S. A., Vazquez, M. J., Williams, L. M., & Diéguez, C. (2007) · Proceedings of The Nutrition Society · doi:10.1017/s0029665107005368 · Cited by 87
Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin—based therapies
Ban, K., Hui, S., Drucker, D. J., & Husain, M. (2009) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2009.04.001 · Cited by 85
Self-citation
Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node
Lubberding, A. F., Veedfald, S., Achter, J. S., Nissen, S. D., Soattin, L., Sorrentino, A., Torres-Vega, E., Linz, B. M., Eggertsen, C. E., Mulvey, J. F., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae120 · Cited by 93
The effects of LY2189265, a long‐acting glucagon‐like peptide‐1 analogue, in a randomized, placebo‐controlled, double‐blind study of overweight/obese patients with type 2 diabetes: the EGO study
Umpierrez, G. E., Blevins, T., Rosenstock, J., Cheng, C., Anderson, J. H., Bastyr, E. J., & for the EGO Study Group (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01366.x · Cited by 84
Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP ‐ 1R activation
Pabreja, K., Mohd, M. A., Koole, C., Wootten, D. L., & Furness, S. G. B. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12313 · Cited by 88
Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by the lower brainstem and sympathoadrenal system
Osaka, T., Endo, M., Yamakawa, M., & Inoue, S. (2005) · Peptides · doi:10.1016/j.peptides.2005.02.016 · Cited by 85
Extrahypothalamic Expression of the Glucagon-Like Peptide-2 Receptor Is Coupled to Reduction of Glutamate-Induced Cell Death in Cultured Hippocampal Cells
Lovshin, J. A., Huang, Q., Seaberg, R. M., Brubaker, P. L., & Drucker, D. J. (2004) · Endocrinology · doi:10.1210/en.2004-0100 · Cited by 84
Self-citation
Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study
Vijiaratnam, N., Girges, C., Auld, G., Chau, M., Maclagan, K., King, A., Skene, S., Chowdhury, K., Hibbert, S., Morris, H., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-047993 · Cited by 84
Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress
Diz-Chaves, Y., Herrera-Pérez, S., González-Matías, L. C., Lamas, J. A., & Mallo, F. (2020) · Nutrients · doi:10.3390/nu12113304 · Cited by 84
Glucagon-like Peptide-1 receptor Tie2+ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction
McLean, B. A., Wong, C. K., Kabir, M. G., & Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101641 · Cited by 82
Self-citation
GLP-1 and Its Analogs: Does Sex Matter?
Börchers, S., & Skibicka, K. P. (2024) · Endocrinology · doi:10.1210/endocr/bqae165 · Cited by 96
Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum
Hansen, L., Hartmann, B., Mineo, H., & Holst, J. J. (2003) · Regulatory Peptides · doi:10.1016/j.regpep.2003.10.021 · Cited by 79
Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake
McKay, N. J., Kanoski, S. E., Hayes, M. R., & Daniels, D. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00472.2011 · Cited by 79
Brain activation following peripheral administration of the GLP-1 receptor agonist exendin-4
Baraboi, E.-D., St-Pierre, D. H., Shooner, J., Timofeeva, E., & Richard, D. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00424.2010 · Cited by 79
Distribution of glucagon-like peptide-1 immunoreactivity in the hypothalamic paraventricular and supraoptic nuclei
Tauchi, M., Zhang, R., D’Alessio, D. A., Stern, J. E., & Herman, J. P. (2008) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2008.07.009 · Cited by 79
GLP ‐1 Receptor Agonists: Effects on Cardiovascular Risk Reduction
Lorber, D. (2012) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12000 · Cited by 78
Effects of GLP-1 Receptor Agonists on Heart Rate and the Autonomic Nervous System Using Holter Electrocardiography and Power Spectrum Analysis of Heart Rate Variability
Nakatani, Y., Kawabe, A., Matsumura, M., Aso, Y., Yasu, T., Banba, N., & Nakamoto, T. (2016) · Diabetes Care · doi:10.2337/dc15-1437 · Cited by 77
LY2189265, a long‐acting glucagon‐like peptide‐1 analogue, showed a dose‐dependent effect on insulin secretion in healthy subjects
Barrington, P. L., Chien, J. Y., Tibaldi, F. S., Showalter, H. D. H., Schneck, K. B., & Ellis, B. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01365.x · Cited by 72
Glucagon-like peptide-1 and glucagon-like peptide-2
Baggio, L. L., & Drucker, D. J. (2004) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2004.08.001 · Cited by 76
Self-citation
The incretins: From the concept to their use in the treatment of type 2 diabetes. Part A: Incretins: Concept and physiological functions
Girard, J. R. (2008) · Diabetes & Metabolism · doi:10.1016/j.diabet.2008.09.001 · Cited by 75
Vagal Afferents Mediate Early Satiation and Prevent Flavour Avoidance Learning in Response to Intraperitoneally Infused Exendin‐4
Labouesse, M. A., Weber‐Stadlbauer, U., Weber, E., Arnold, M., Langhans, W., & Pacheco‐López, G. (2012) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2012.02364.x · Cited by 71
Cardiovascular Comorbidities of Type 2 Diabetes Mellitus: Defining the Potential of Glucagonlike peptide–1-Based Therapies
CHILTON, R. J., Wyatt, J., Nandish, S., OLIVEROS, R. A., & Lujan, M. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.004 · Cited by 68
Deciphering Metabolic Messages From the Gut Drives Therapeutic Innovation: The 2014 Banting Lecture
Drucker, D. J. (2015) · Diabetes · doi:10.2337/db14-1514 · Cited by 70
Self-citation
Treatment with a GLP−1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders
Mansur, R. B., Zugman, A., Ahmed, J., Cha, D. S., Subramaniapillai, M., Lee, Y. L., Lovshin, J. A., Lee, J. G., Lee, J.-H., Drobinin, V., et al. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.08.433 · Cited by 68
Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix
Robinson, E., Cassidy, R. S., Tate, M., Zhao, Y., Lockhart, S. M., Calderwood, D., Church, R. H., McGahon, M. K., Brazil, D. P., McDermott, B. J., et al. (2015) · Basic Research in Cardiology · doi:10.1007/s00395-015-0476-7 · Cited by 71
Time course and mechanisms of the anti‐hypertensive and renal effects of liraglutide treatment
von Scholten, B. J., Lajer, M., Goetze, J. P., Persson, F., & Rossing, P. (2015) · Diabetic Medicine · doi:10.1111/dme.12594 · Cited by 73
Progesterone Receptor Membrane Component 1 Is a Functional Part of the Glucagon-like Peptide-1 (GLP-1) Receptor Complex in Pancreatic β Cells
Zhang, M., Robitaille, M., Showalter, A. D., Huang, X., Liu, Y., Bhattacharjee, A., Willard, F. S., Han, J., Froese, D. S., Li, W., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.040196 · Cited by 68
Vascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance
Pujadas, G., & Drucker, D. J. (2016) · Endocrine Reviews · doi:10.1210/er.2016-1078 · Cited by 67
Self-citation
Substance P Increases Sympathetic Activity During Combined Angiotensin-Converting Enzyme and Dipeptidyl Peptidase-4 Inhibition
Devin, J. K., Pretorius, M., Nian, H., Yu, C., Billings, F. T., & Brown, N. J. (2014) · Hypertension · doi:10.1161/hypertensionaha.113.02767 · Cited by 66
Heart Failure and Loss of Metabolic Control
Wang, Z. V., Li, D. ‘., & Hill, J. A. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000054 · Cited by 63
Differences in the Central Anorectic Effects of Glucagon-Like Peptide-1 and Exendin-4 in Rats
Barrera, J. G., D’Alessio, D. A., Drucker, D. J., Woods, S. C., & Seeley, R. J. (2009) · Diabetes · doi:10.2337/db09-0281 · Cited by 63
Self-citation
The physiological role of the brain GLP-1 system in stress
Holt, M. K., & Trapp, S. (2016) · Cogent Biology · doi:10.1080/23312025.2016.1229086 · Cited by 64
Hepatic‐Portal Vein Infusions of Glucagon‐Like Peptide‐1 Reduce Meal Size and Increase c‐Fos Expression in the Nucleus Tractus Solitarii, Area Postrema and Central Nucleus of the Amygdala in Rats
Baumgartner, I., Pacheco‐López, G., Rüttimann, E. B., Arnold, M., Asarian, L., Langhans, W., Geary, N., & Hillebrand, J. J. G. (2010) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2010.01995.x · Cited by 64
CNS GLP-1 regulation of peripheral glucose homeostasis
Sandoval, D. A. (2008) · Physiology & Behavior · doi:10.1016/j.physbeh.2008.04.018 · Cited by 59
Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium
DeNicola, M., Du, J., Wang, Z., Yano, N., Zhang, L., Wang, Y., Qin, G., Zhuang, S., & Zhao, T. C. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00109.2014 · Cited by 63
Exendin-4 inhibits structural remodeling and improves Ca 2+ homeostasis in rats with heart failure via the GLP-1 receptor through the eNOS/cGMP/PKG pathway
Chen, J., Wang, D., Wang, F., Shi, S., Chen, Y., Yang, B., Tang, Y., & Huang, C. (2017) · Peptides · doi:10.1016/j.peptides.2017.02.008 · Cited by 64
Preproglucagon (PPG) neurons innervate neurochemicallyidentified autonomic neurons in the mouse brainstem
Llewellyn‐Smith, I., Gnanamanickam, G. J. E., Reimann, F. M., Gribble, F. M., & Trapp, S. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.09.071 · Cited by 61
Regulation of lipid metabolism by energy availability: a role for the central nervous system
Nogueiras, R., López, M., & Diéguez, C. (2009) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00669.x · Cited by 67
Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system
Pérez–Tilve, D., González-Matías, L. C., Aulinger, B. A., Álvarez-Crespo, M., Gil‐Lozano, M., Alvarez, E., Andrade-Olivie, A. M., Tschöp, M. H., D’Alessio, D. A., & Mallo, F. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00464.2009 · Cited by 62
Circulating glucagon-like peptide-1 (GLP-1) inhibits eating in male rats by acting in the hindbrain and without inducing avoidance
Punjabi, M., Arnold, M., Rüttimann, E., Graber, M., Geary, N., Pacheco-López, G., & Langhans, W. (2014) · Endocrinology · doi:10.1210/en.2013-1447 · Cited by 59
Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advances
Asmar, M., & Holst, J. J. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283339051 · Cited by 60
Multifaceted Roles of GLP-1 and Its Analogs: A Review on Molecular Mechanisms with a Cardiotherapeutic Perspective
Pandey, S., Mangmool, S., & Parichatikanond, W. (2023) · Pharmaceuticals · doi:10.3390/ph16060836 · Cited by 61
Exenatide reduces food intake and activates the enteric nervous system of the gastrointestinal tract and the dorsal vagal complex of the hindbrain in the rat by a GLP-1 receptor
Washington, M. C., Raboin, S. J., Thompson, W., Larsen, C. J., & Sayegh, A. I. (2010) · Brain Research · doi:10.1016/j.brainres.2010.05.002 · Cited by 58
Beyond glucose lowering: Glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system
Vergès, B., Bonnard, C., & Renard, E. (2011) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.07.001 · Cited by 58
The entero-insular axis: implications for human metabolism
Ranganath, L. R. (2007) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2008.008 · Cited by 58
Incretins
Wu, T., Rayner, C. K., & Horowitz, M. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_9 · Cited by 60
Glucagon-like peptide-1 reduces the pulsatile component of testosterone secretion in healthy males
Jeibmann, A., Zahedi, S., Simoni, M., Nieschlag, E., & Byrne, M. M. (2005) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2005.01542.x · Cited by 57
Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males
Smits, M. M., Muskiet, M. H. A., Tonneijck, L., Hoekstra, T., Kramer, M. H. H., Diamant, M., & van Raalte, D. H. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12843 · Cited by 60
Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor
Sowden, G. L., Drucker, D. J., Weinshenker, D., & Swoap, S. J. (2006) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00405.2006 · Cited by 58
Self-citation
Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson's with pre-existing diabetes
Elbassuoni, E., & Ahmed, R. F. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.104583 · Cited by 57
Irisin and Incretin Hormones: Similarities, Differences, and Implications in Type 2 Diabetes and Obesity
Marrano, N., Biondi, G., Borrelli, A., Cignarelli, A., Perrini, S., Laviola, L., Giorgino, F., & Natalicchio, A. (2021) · Biomolecules · doi:10.3390/biom11020286 · Cited by 56
Experimental dissociation of neural circuits underlying conditioned avoidance and hypophagic responses to lithium chloride
Rinaman, L., & Dzmura, V. M. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00393.2007 · Cited by 56
Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk
Mannucci, E., & Rotella, C. M. (2008) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.08.002 · Cited by 57
Glucosensing in the gastrointestinal tract: Impact on glucose metabolism
Fournel, A., Marlin, A., Abot, A., Pasquio, C., Cirillo, C., Cani, P. D., & Knauf, C. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00015.2016 · Cited by 57
Glucagon-Like Peptide-1 and Energy Homeostasis3
Burcelin, R., Cani, P. D., & Knauf, C. (2007) · Journal of Nutrition · doi:10.1093/jn/137.11.2534s · Cited by 56
Approach to diabetes management in patients with CVD
Lathief, S., & Inzucchi, S. E. (2015) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.05.005 · Cited by 55
Endogenous Glucagon-Like Peptide-1 Reduces Drinking Behavior and Is Differentially Engaged by Water and Food Intakes in Rats
McKay, N. J., Galante, D. L., & Daniels, D. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3267-14.2014 · Cited by 55
The thyrotropin-releasing hormone gene is regulated by thyroid hormone at the level of transcription in vivo
Sugrue, M. L., Vella, K. R., Morales, C., Lopez, M. E., & Hollenberg, A. N. (2010) · Endocrinology · doi:10.1210/en.2009-0976 · Cited by 54
Self-citation
Single Dose GLP-1-Tf Ameliorates Myocardial Ischemia/Reperfusion Injury
Matsubara, M., Kanemoto, S., Leshnower, B. G., Albone, E. F., Hinmon, R., Plappert, T. A., Gorman, J. H., & Gorman, R. C. (2009) · Journal of Surgical Research · doi:10.1016/j.jss.2009.03.016 · Cited by 54
The protective role of DPP4 inhibitors in atherosclerosis
Liu, H., Guo, L., Xing, J., Li, P., Sang, H., Hu, X., Du, Y., Zhao, L., Song, R., & Gu, H. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173037 · Cited by 54
Pulmonary GLP-1 Receptor Increases at Birth and Exogenous GLP-1 Receptor Agonists Augmented Surfactant-Protein Levels in Litters From Normal and Nitrofen-Treated Pregnant Rats
Romaní-Pérez, M., Outeiriño-Iglesias, V., Gil-Lozano, M., González-Matías, L. C., Mallo, F., & Vigo, E. (2013) · Endocrinology · doi:10.1210/en.2012-1786 · Cited by 51
Beyond Glycemic Control in Diabetes Mellitus: Effects of Incretin-Based Therapies on Bone Metabolism
Ceccarelli, E., Guarino, E., Merlotti, D., Patti, A., Gennari, L., Nuti, R., & Dotta, F. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00073 · Cited by 51
Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo
Nathanson, D., Erdogdu, Ö., Pernow, J., Zhang, Q., & Nyström, T. (2009) · Regulatory Peptides · doi:10.1016/j.regpep.2009.07.003 · Cited by 51
SF-1 expression in the hypothalamus is required for beneficial metabolic effects of exercise
Fujikawa, T., Castorena, C. M., Pearson, M. J., Kusminski, C. M., Ahmed, N. I., Battiprolu, P. K., Kim, K. W., Lee, S., Hill, J. A., Scherer, P. E., et al. (2016) · eLife · doi:10.7554/elife.18206 · Cited by 51
Self-citation
Mesenteric Vasoconstriction and Hindquarters Vasodilatation Accompany the Pressor Actions of Exendin-4 in Conscious Rats
Gardiner, S. M., March, J. E., Kemp, P. A., & Bennett, T. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.093104 · Cited by 50
Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors
Cherney, D. Z. I., Udell, J. A., & Drucker, D. J. (2021) · Med · doi:10.1016/j.medj.2021.10.004 · Cited by 54
Self-citation
Evidence for a Gut-Brain Axis Used by Glucagon-like Peptide-1 to Elicit Hyperglycaemia in Fish
Polakof, S., Míguez, J. M., & Soengas, J. L. (2011) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2011.02137.x · Cited by 50
Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome
Camilleri, M., Vázquez‐Roque, M. I., Iturrino, J., Boldingh, A., Burton, D. B., McKinzie, S., Wong, B. S., Rao, A. S., Kenny, E., Månsson, M., et al. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00076.2012 · Cited by 50
Effects of intracerebroventricularly injected glucagon-like peptide-1 on cardiovascular parameters; role of central cholinergic system and vasopressin
Işbil-Büyükcoşkun, N., & Süyen, G. G. (2003) · Regulatory Peptides · doi:10.1016/j.regpep.2003.10.025 · Cited by 49
Hypertension in obesity: is leptin the culprit?
Simonds, S. E., & Cowley, M. A. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2013.01.004 · Cited by 50
Positron emission tomography imaging of the glucagon-like peptide-1 receptor in healthy and streptozotocin-induced diabetic pigs
Nalin, L., Selvaraju, R. K., Velikyan, I., Berglund, M., Andréasson, S., Wikstrand, A., Rydén, A., Lubberink, M., KANDEEL, F. R., Nyman, G. C., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2745-3 · Cited by 48
Central Nervous System GLP-1 Receptors Regulate Islet Hormone Secretion and Glucose Homeostasis in Male Rats
Jessen, L., Smith, E. P., Ulrich‐Lai, Y. M., Herman, J. P., Seeley, R. J., Sandoval, D. A., & D’Alessio, D. A. (2017) · Endocrinology · doi:10.1210/en.2016-1826 · Cited by 50
Effects of exogenous glucagon-like peptide-1 on blood pressure, heart rate, gastric emptying, mesenteric blood flow and glycaemic responses to oral glucose in older individuals with normal glucose tolerance or type 2 diabetes
Trahair, L. G., Horowitz, M., Stevens, J. E., Feinle‐Bisset, C., Standfield, S., Piscitelli, D., Rayner, C. K., Deane, A. M., & Jones, K. L. (2015) · Diabetologia · doi:10.1007/s00125-015-3638-0 · Cited by 49
Brainstem sensing of meal-related signals in energy homeostasis
Young, A. A. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.03.019 · Cited by 50
Cognitive dysfunction and metabolic comorbidities in mood disorders: A repurposing opportunity for glucagon-like peptide 1 receptor agonists?
Mansur, R. B., Lee, Y. L., Subramaniapillai, M., Brietzke, E. M., & McIntyre, R. S. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.048 · Cited by 48
The role of nucleus of the solitary tract glucagon‐like peptide‐1 and prolactin‐releasing peptide neurons in stress: anatomy, physiology and cellular interactions
Holt, M. K., & Rinaman, L. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15576 · Cited by 48
Extra‐pancreatic effects of incretin‐based therapies: potential benefit for cardiovascular‐risk management in type 2 diabetes
van Genugten, R. E., Möller-Goede, D. L., van Raalte, D. H., & Diamant, M. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12050 · Cited by 46
Long Term Exendin-4 Treatment Reduces Food Intake and Body Weight and Alters Expression of Brain Homeostatic and Reward Markers
Yang, Y., Moghadam, A. A., Cordner, Z. A., Liang, N., & Moran, T. H. (2014) · Endocrinology · doi:10.1210/en.2014-1052 · Cited by 44
Central Glucagon-like Peptide-1 Receptor Signaling via Brainstem Catecholamine Neurons Counteracts Hypertension in Spontaneously Hypertensive Rats
Katsurada, K., Nakata, M., Saito, T., Zhang, B., Maejima, Y., Nandi, S. S., Sharma, N. M., Patel, K. P., Kario, K., & Yada, T. (2019) · Scientific Reports · doi:10.1038/s41598-019-49364-x · Cited by 46
Lesions of area postrema and subfornical organ alter exendin-4-induced brain activation without preventing the hypophagic effect of the GLP-1 receptor agonist
Baraboi, E., Smith, P., Ferguson, A. V., & Richard, D. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00326.2009 · Cited by 44
Direct cardiovascular effects of glucagon like peptide-1
Sheikh, A. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-47 · Cited by 45
Role of central glucagon-like peptide-1 in hypothalamo-pituitary-adrenocortical facilitation following chronic stress
Tauchi, M., Zhang, R., D’Alessio, D. A., Seeley, R. J., & Herman, J. P. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.11.016 · Cited by 47
Effects of meal and incretins in the regulation of splanchnic blood flow
Koffert, J., Honka, H., Teuho, J., Kauhanen, S. P., Hurme, S. A. M., Parkkola, R. K., Oikonen, V., Mari, A., Lindqvist, A., Wierup, N., et al. (2017) · Endocrine Connections · doi:10.1530/ec-17-0015 · Cited by 45
Exenatide Improves Hypertension in a Rat Model of the Metabolic Syndrome
Laugero, K. D., Stonehouse, A. H., Guss, S., Landry, J., Vu, C., & Parkes, D. G. (2009) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2008.0095 · Cited by 42
Exendin‐4 inhibits iNOS expression at the protein level in LPS‐stimulated Raw264.7 macrophage by the activation of cAMP/PKA pathway
Chang, S., Kim, D., Ryu, G. R., Ko, S., Jeong, I., Ahn, Y., Jo, Y., & Kim, M. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24425 · Cited by 44
Effects of GLP-1 receptor agonists on arrhythmias and its subtypes in patients with type 2 diabetes: A systematic review and meta-analysis
Wei, J., Wang, R., Ye, H., Wang, Y., Wang, L., & Zhang, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.910256 · Cited by 44
Hypothalamic control of energy and glucose metabolism
Sisley, S. R., & Sandoval, D. A. (2011) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-011-9189-x · Cited by 45
An overview of new GLP-1 receptor agonists for type 2 diabetes
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1123249 · Cited by 49

Authors: Yamamoto, H., Lee, C. E., Marcus, J. N., Williams, T. D., Overton, J. M., Lopez, M. E., Hollenberg, A. N., Baggio, L., Saper, C. B., Drucker, D. J., & Elmquist, J. K.
Affiliations: Beth Israel Deaconess Medical Center (US)
Florida State University (US)
University of Toronto (CA)
Corresponding author: Elmquist, Joel K.
ORCID: Yamamoto, Hiroshi
Lee, Charlotte E.
Lopez, Marisol E.
Hollenberg, Anthony N.
Saper, Clifford B.
Drucker, Daniel J.
Elmquist, Joel K.
Venue: Journal of Clinical Investigation
Publisher: American Society for Clinical Investigation
Published: 2002-07-01
Volume: 110
Issue: 1
Pages: 43-52
ISSN: 0021-9738 (ISSN-L)
DOI: 10.1172/jci0215595
OpenAlex: W4252795044
Cited by: 429
References: 44
Citations by year: 2026: 11 · 2025: 4 · 2024: 11 · 2023: 7 · 2022: 14 · 2021: 19 · 2020: 16 · 2019: 15 · 2018: 13 · 2017: 18 · 2016: 21 · 2015: 25 · 2014: 30 · 2013: 32 · 2012: 30
FWCI: 4.30
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Investigation (publishedVersion)
Funders: National Institutes of Health
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords: glucagon-like peptide-1, GLP-1 receptor agonists, blood pressure, heart rate, autonomic regulation, sympathetic nervous system, catecholaminergic neurons, adrenal medulla, Fos expression, tyrosine hydroxylase, brainstem, cardiovascular response, incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks